|
The 5000% case: a glimpse into the financial issue of lung cancer treatment |
journalArticle |
2016 |
Remon, J.; Bonastre, J.; Besse, B. |
|
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial |
journalArticle |
2016 |
Ribrag, V.; Koscielny, S.; Bosq, J.; Leguay, T.; Casasnovas, O.; Fornecker, L. M.; Recher, C.; Ghesquieres, H.; Morschhauser, F.; Girault, S.; Le Gouill, S.; Ojeda-Uribe, M.; Mariette, C.; Cornillon, J.; Cartron, G.; Verge, V.; Chassagne-Clement, C.; Dombret, H.; Coiffier, B.; Lamy, T.; Tilly, H.; Salles, G. |
|
Concordance between HER-2 status determined by qPCR in Fine Needle Aspiration Cytology (FNAC) samples compared with IHC and FISH in Core Needle Biopsy (CNB) or surgical specimens in breast cancer patients |
journalArticle |
2016 |
Rodriguez, C.; Suciu, V.; Poterie, A.; Lacroix, L.; Miran, I.; Boichard, A.; Delaloge, S.; Deneuve, J.; Azoulay, S.; Mathieu, M. C.; Valent, A.; Michiels, S.; Arnedos, M.; Vielh, P. |
|
Incorporation of nested frailties into semiparametric multi-state models |
journalArticle |
2016 |
Rotolo, F.; Rondeau, V.; Legrand, C. |
|
Modalités de surveillance des patients suivis pour un cancer de la prostate avancé : résultats d’une enquête nationale de pratique |
journalArticle |
2016 |
Rozet, F.; Roupret, M.; Hennequin, C.; Massard, C.; Blanchard, P.; Le moulec, S. |
|
Uncovering Professional Attitudes Toward Treatment of Rare Carcinomas of the Breast: An International Practice e-Survey Involving 32 Countries |
journalArticle |
2016 |
Saghatchian, M.; Fadoukhair, Z.; Hofert, K.; Lanoy, E.; Mathieu, M. C.; Mazouni, C.; Delaloge, S. |
|
Towards understanding the breast cancer epigenome: a comparison of genome-wide DNA methylation and gene expression data |
journalArticle |
2016 |
Singhal, S. K.; Usmani, N.; Michiels, S.; Metzger-Filho, O.; Saini, K. S.; Kovalchuk, O.; Parliament, M. |
|
Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes |
journalArticle |
2016 |
Sio, T. T.; Lin, H. K.; Shi, Q.; Gunn, G. B.; Cleeland, C. S.; Lee, J. J.; Hernandez, M.; Blanchard, P.; Thaker, N. G.; Phan, J.; Rosenthal, D. I.; Garden, A. S.; Morrison, W. H.; Fuller, C. D.; Mendoza, T. R.; Mohan, R.; Wang, X. S.; Frank, S. J. |
|
The protein phosphatase 2A regulatory subunit PR70 is a gonosomal melanoma tumor suppressor gene |
journalArticle |
2016 |
van Kempen, L. C.; Redpath, M.; Elchebly, M.; Klein, K. O.; Papadakis, A. I.; Wilmott, J. S.; Scolyer, R. A.; Edqvist, P. H.; Ponten, F.; Schadendorf, D.; van Rijk, A. F.; Michiels, S.; Dumay, A.; Helbling-Leclerc, A.; Dessen, P.; Wouters, J.; Stass, M.; Greenwood, C. M.; Ghanem, G. E.; van den Oord, J.; Feunteun, J.; Spatz, A. |
|
Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification |
journalArticle |
2017 |
Andreiuolo, F.; Le Teuff, G.; Bayar, M. A.; Kilday, J. P.; Pietsch, T.; von Bueren, A. O.; Witt, H.; Korshunov, A.; Modena, P.; Pfister, S. M.; Pagès, M.; Castel, D.; Giangaspero, F.; Chimelli, L.; Varlet, P.; Rutkowski, S.; Frappaz, D.; Massimino, M.; Grundy, R.; Grill, J. |
|
Safety, tolerability and antitumour activity of LY2780301 (p70S6K/AKT inhibitor) in combination with gemcitabine in molecularly selected patients with advanced or metastatic cancer: a phase IB dose escalation study |
journalArticle |
2017 |
Angevin, E.; Cassier, P. A.; Italiano, A.; Goncalves, A.; Gazzah, A.; Terret, C.; Toulmonde, M.; Gravis, G.; Varga, A.; Parlavecchio, C.; Paci, A.; Poinsignon, V.; Soria, J. C.; Drubay, D.; Hollebecque, A. |
|
Optimizing Local Control in High-Grade Uterine Sarcoma: Adjuvant Vaginal Vault Brachytherapy as Part of a Multimodal Treatment |
journalArticle |
2017 |
Annede, P.; Gouy, S.; Mazeron, R.; Bentivegna, E.; Maroun, P.; Petit, C.; Dumas, I.; Leary, A.; Genestie, C.; Lhomme, C.; Deutsch, E.; Morice, P.; Pautier, P.; Haie-Meder, C.; Chargari, C. |
|
Inflammatory bowel diseases activity in patients undergoing pelvic radiation therapy |
journalArticle |
2017 |
Annede, P.; Seisen, T.; Klotz, C.; Mazeron, R.; Maroun, P.; Petit, C.; Deutsch, E.; Bossi, A.; Haie-Meder, C.; Chargari, C.; Blanchard, P. |
|
Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials |
journalArticle |
2017 |
Arnold, D.; Lueza, B.; Douillard, J. Y.; Peeters, M.; Lenz, H. J.; Venook, A.; Heinemann, V.; Van Cutsem, E.; Pignon, J. P.; Tabernero, J.; Cervantes, A.; Ciardiello, F. |
|
In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies? |
journalArticle |
2017 |
Aspeslagh, S.; Matias, M.; Palomar, V.; Dercle, L.; Lanoy, E.; Soria, J. C.; Postel-Vinay, S. |
|
A Novel Spectroscopically Determined Pharmacodynamic Biomarker for Skin Toxicity in Cancer Patients Treated with Targeted Agents |
journalArticle |
2017 |
Azan, A.; Caspers, P. J.; Bakker Schut, T. C.; Roy, S.; Boutros, C.; Mateus, C.; Routier, E.; Besse, B.; Planchard, D.; Seck, A.; Kamsu Kom, N.; Tomasic, G.; Koljenovic, S.; Noordhoek Hegt, V.; Texier, M.; Lanoy, E.; Eggermont, A. M.; Paci, A.; Robert, C.; Puppels, G. J.; Mir, L. M. |
|
Clinical outcomes after interstitial brachytherapy for early-stage nasal squamous cell carcinoma |
journalArticle |
2017 |
Bacorro, W.; Escande, A.; Temam, S.; Dumas, I.; Routier, E.; Gensse, M. C.; Blanchard, P.; Janot, F.; Mateus, C.; Tao, Y.; Robert, C.; Deutsch, E.; Haie-Meder, C.; Chargari, C. |
|
Phase I trial of bortezomib daily dose: safety, pharmacokinetic profile, biological effects and early clinical evaluation in patients with advanced solid tumors |
journalArticle |
2017 |
Bahleda, R.; Le Deley, M. C.; Bernard, A.; Chaturvedi, S.; Hanley, M.; Poterie, A.; Gazzah, A.; Varga, A.; Touat, M.; Deutsch, E.; Massard, C.; Van De Velde, H.; Hollebecque, A.; Sallansonnet-Froment, M.; Ricard, D.; Taillia, H.; Angevin, E.; Ribrag, V.; Soria, J. C. |
|
Revisiting the definition of dose-limiting toxicities in paediatric oncology phase I clinical trials: An analysis from the Innovative Therapies for Children with Cancer Consortium |
journalArticle |
2017 |
Bautista, F.; Moreno, L.; Marshall, L.; Pearson, A. D. J.; Geoerger, B.; Paoletti, X. |
|
Statistical approaches for evaluating body composition markers in clinical cancer research |
journalArticle |
2017 |
Bayar, M. A.; Antoun, S.; Lanoy, E. |
|
Randomized phase II trial comparing molecularly targeted therapy based on tumor molecular profiling versus conventional therapy in patients with refractory cancer: cross-over analysis from the SHIVA trial |
journalArticle |
2017 |
Belin, L.; Kamal, M.; Mauborgne, C.; Plancher, C.; Mulot, F.; Delord, J. P.; Gonçalves, A.; Gavoille, C.; Dubot, C.; Isambert, N.; Campone, M.; Trédan, O.; Ricci, F.; Alt, M.; Loirat, D.; Sablin, M. P.; Paoletti, X.; Servois, V.; Le Tourneau, C. |
|
Lenvatinib for the treatment of radio-iodine refractory thyroid cancer in real-life practice |
journalArticle |
2017 |
Berdelou, A.; Borget, I.; Godbert, Y.; Nguyen, T.; Garcia, M. E.; Chougnet, C. N.; Ferru, A.; Buffet, C.; Chabre, O.; Huillard, O.; Leboulleux, S.; Schlumberger, M. |
|
Pazopanib or placebo in completely resected stage I NSCLC patients: results of the phase II IFCT-0703 trial |
journalArticle |
2017 |
Besse, B.; Mazières, J.; Ribassin-Majed, L.; Barlesi, F.; Bennouna, J.; Gervais, R.; Moreau, L.; Berard, H.; Debieuvre, D.; Molinier, O.; Moro-Sibilot, D.; Souquet, P. J.; Jacquot, S.; Petit, L.; Lena, H.; Pignon, J. P.; Lacas, B.; Morin, F.; Milleron, B.; Zalcman, G.; Soria, J. C. |
|
Burnout among young European oncologists: a call for action |
journalArticle |
2017 |
Blanchard, P. |
|
Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis |
journalArticle |
2017 |
Blanchard, P.; Belkhir, F.; Temam, S.; El Khoury, C.; De Felice, F.; Casiraghi, O.; Patrikidou, A.; Mirghani, H.; Levy, A.; Even, C.; Gorphe, P.; Nguyen, F.; Janot, F.; Tao, Y. |
|
Radiation therapy to the primary in metastatic prostate cancer: palliation only or altering tumor biology? |
journalArticle |
2017 |
Blanchard, P.; Bossi, A.; Fizazi, K. |
|
Quality of life after brachytherapy or bilateral nerve-sparing robot-assisted radical prostatectomy for prostate cancer: a prospective cohort |
journalArticle |
2017 |
Blanchard, P.; Davis, J. W.; Frank, S. J.; Kim, J.; Pettaway, C. A.; Pugh, T. J.; Pisters, L. L.; Ward, J. F.; Choi, S.; Chapin, B. F.; Hoffman, K.; Navai, N.; Achim, M.; McGuire, S. E.; Matin, S. F.; Nguyen, Q.; Mahmood, U.; Graber, W. J.; Chen, H. C.; Wang, X.; Kuban, D. A. |
|
In Regard to Arthurs et al |
journalArticle |
2017 |
Blanchard, P.; Garden, A. S. |
|
Clinical use of magnetic resonance imaging across the prostate brachytherapy workflow |
journalArticle |
2017 |
Blanchard, P.; Menard, C.; Frank, S. J. |
|
Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients |
journalArticle |
2017 |
Boros, A.; Lacroix, L.; Lacas, B.; Adam, J.; Pignon, J. P.; Caramella, C.; Planchard, D.; de Montpreville, V.; Deutsch, E.; Levy, A.; Besse, B.; Le Pechoux, C. |
|
Choline Positron Emission Tomography/Computed Tomography for Selection of Patients for Salvage Strategies After Primary Local Treatment of Prostate Cancer and Rising Prostate-specific Antigen: Ready for Prime Time? |
journalArticle |
2017 |
Bossi, A.; Mottet, N.; Blanchard, P. |
|
Bayesian survival analysis in clinical trials: What methods are used in practice? |
journalArticle |
2017 |
Brard, C.; Le Teuff, G.; Le Deley, M. C.; Hampson, L. V. |
|
Patients' perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study |
journalArticle |
2017 |
Bredart, A.; Bodson, S.; Le Tourneau, C.; Flahault, C.; Bonnetain, F.; Beaudeau, A.; Coquan, E.; Dolbeault, S.; Paoletti, X. |
|
Lung Adenocarcinoma as Part of the Li-Fraumeni Syndrome Spectrum: Preliminary Data of the LIFSCREEN Randomized Clinical Trial |
journalArticle |
2017 |
Caron, O.; Frebourg, T.; Benusiglio, P. R.; Foulon, S.; Brugières, L. |
|
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab |
journalArticle |
2017 |
Chaput, N.; Lepage, P.; Coutzac, C.; Soularue, E.; Le Roux, K.; Monot, C.; Boselli, L.; Routier, E.; Cassard, L.; Collins, M.; Vaysse, T.; Marthey, L.; Eggermont, A.; Asvatourian, V.; Lanoy, E.; Mateus, C.; Robert, C.; Carbonnel, F. |
|
Angiogenesis inhibition in the second-line treatment of metastatic colorectal cancer: A systematic review and pooled analysis |
journalArticle |
2017 |
Chebib, R.; Verlingue, L.; Cozic, N.; Faron, M.; Burtin, P.; Boige, V.; Hollebecque, A.; Malka, D. |
|
Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study |
journalArticle |
2017 |
Colomba, E.; Le Teuff, G.; Eisen, T.; Stewart, G. D.; Fife, K.; Larkin, J.; Biondo, A.; Pickering, L.; Srinivasan, A.; Boyle, H.; Derosa, L.; Sternberg, C. N.; Recine, F.; Ralph, C.; Saldana, C.; Barthélémy, P.; Bernhard, J. C.; Gurney, H.; Verhoest, G.; Vauleon, E.; Bigot, P.; Berger, J.; Pfister, C.; Gravis, G.; Rodier, J. M.; Culine, S.; Caty, A.; Rolland, F.; Priou, F.; Escudier, B.; Albiges, L. |
|
Use of Low-Thrombin Fibrin Sealant Glue After Axillary Lymphadenectomy for Breast Cancer to Reduce Hospital Length and Seroma |
journalArticle |
2017 |
Conversano, A.; Mazouni, C.; Thomin, A.; Gaudin, A.; Fournier, M.; Rimareix, F.; Bonastre, J. |
|
Radiation-induced neurocognitive dysfunction in head and neck cancer patients |
journalArticle |
2017 |
De Felice, F.; Blanchard, P. |
|
Prognostic factors of successful on-purpose tumor biopsies in metastatic cancer patients included in the SHIVA prospective clinical trial |
journalArticle |
2017 |
Desportes, E.; Wagner, M.; Kamal, M.; Salomon, A. V.; Deniziaut, G.; Pierron, G.; Rouleau, E.; Jouffroy, T.; Le Tourneau, C.; Paoletti, X.; Servois, V. |